Based on current operating plans, Xencor (XNCR) expects to end 2025 with between $535 million and $585 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- XNCR Upcoming Earnings Report: What to Expect?
- Xencor’s Promising Pipeline and Strategic Positioning Justify Buy Rating
- Xencor’s Promising Biotech Innovations and Strategic Growth Potential Justify Buy Rating
- Promising Outlook for Xencor’s XmAb942 Program Amidst Stock Decline
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue